Table 1.
Patient and clinicopathological variables.
| Variable | Overall (n = 239) |
HAIC+Sys (n = 79) |
Sys (n = 77) |
Surgery alone (n = 83) |
p value |
|---|---|---|---|---|---|
| Age at liver resection (years) | 60.8 (18.9 – 86.8) | 57.5 (37.2 – 81.3) | 59.2 (18.9 – 82.7) | 67.9 (34.3 – 86.8) | <0.001 |
| Body mass index | 26.5 (17.2 – 50.5) | 27.4 (17.9 – 41) | 26.3 (19.5 – 50.5) | 25.8 (17.2 – 37.6) | 0.075 |
| Number of resected liver segments | 3 (0.2 – 6) | 4 (1 – 5.2) | 4 (0.2 – 6) | 2 (0.2 – 6) | 0.003 |
| Size of largest CLM (cm) | 3.4 (0.7 – 16.5) | 3 (0.7 – 13) | 3.5 (1.1 – 16.5) | 3.5 (1.2 – 11) | 0.523 |
| Estimated blood loss at hepatectomy (mL) | 445 (10 – 5500) | 450 (50 – 5500) | 500 (50 – 2600) | 350 (10 – 2200) | 0.107 |
| CEA prior to liver resection (µg/L) | 14.4 (0.5 – 2375) | 13.2 (0.5 – 2375) | 18 (0.9 – 387) | 13.3 (1.3 – 823) | 0.298 |
| Sex | 0.150 | ||||
| Male | 131 | 44 (33.6) | 48 (36.6) | 39 (29.8) | |
| Female | 108 | 35 (32.4) | 29 (26.9) | 44 (40.7) | |
| Location of primary | 0.338 | ||||
| Right colon | 49 | 22 (44.9) | 15 (30.6) | 12 (24.5) | |
| Left colon | 136 | 41 (30.1) | 44 (32.4) | 51 (37.5) | |
| Rectum | 54 | 16 (29.6) | 18 (33.3) | 20 (37) | |
| Type of chemotherapy after primary resection | 0.043 | ||||
| 5-FU alone | 178 | 51 (28.7) | 60 (33.7) | 67 (37.6) | |
| 5-FU + oxaliplatin/irinotecan | 61 | 28 (45.9) | 17 (27.9) | 16 (26.2) | |
| CRS | 0.149 | ||||
| Low risk (0–3) | 218 | 76 (34.9) | 69 (31.7) | 73 (33.5) | |
| High risk (4–5) | 21 | 3 (14.3) | 8 (38.1) | 10 (47.6) | |
| Disease-free interval (DFI) | 0.385 | ||||
| ≥12 months | 136 | 40 (29.4) | 46 (33.8) | 50 (36.8) | |
| <12 months | 103 | 39 (37.9) | 31 (30.1) | 33 (32) | |
| Number of liver tumors | 0.078 | ||||
| Single lesion | 117 | 34 (29.1) | 34 (29.1) | 49 (41.9) | |
| Multiple lesions | 122 | 45 (36.9) | 43 (35.2) | 34 (27.9) | |
| Largest CLM tumor size | 0.979 | ||||
| ≤5cm | 187 | 62 (33.2) | 60 (32.1) | 65 (34.8) | |
| >5cm | 51 | 17 (33.3) | 17 (33.3) | 17 (33.3) | |
| N/A | 1 | 0 (0) | 0 (0) | 1 (100) | |
| Neoadjuvant chemotherapy prior hepatectomy | 0.836 | ||||
| No | 206 | 67 (32.5) | 66 (32) | 73 (35.4) | |
| Yes | 33 | 12 (36.4) | 11 (33.3) | 10 (30.3) | |
| Surgical era | 0.012 | ||||
| 1992–2001 | 144 | 38 (26%) | 47 (34%) | 59 (41%) | |
| 2002–2014 | 95 | 41 (43%) | 30 (32%) | 24 (25%) |
HAIC=hepatic arterial infusion chemotherapy; Sys=systemic chemotherapy; 5-FU=5-fluorouracil; CLM=colorectal liver metastasis;
CEA=carcinoembryonic antigen; CRS=clinical risk score; N/A=not available
For continuous variables, median (range) is shown. For categorical variables, n (row percentage) is shown